Objectives: Mycoplasma pneumoniae is a frequent cause of human lower respiratory tract infections (LRTIs) for which macrolides are the treatment of choice. The aim of this study was to determine the rate of macrolide resistance and to subtype M. pneumoniae strains in Italy.
Introduction
Mycoplasma pneumoniae is a common bacterial cause of upper and lower respiratory tract infections (LRTIs), especially in children. In school-aged children and young adults with community-acquired pneumonia, it accounts for up to 40% -50% of cases. 1 Epidemic outbreaks have been registered at time intervals of 3 -7 years, thus leading to the hypothesis that different subtypes of M. pneumoniae with variable antigenic properties are circulating in the human population. 2 M. pneumoniae infections can usually be effectively treated with macrolides, which are generally considered the first-choice antibiotics in children and adults. 3 However, macrolide resistance has been observed in a number of countries, including France, the USA and Denmark, 1 and has reached a rate of 90% in China. 4 Macrolide resistance phenotypes are defined by specific point mutations in the V domain of the single-copy 23S rRNA gene of M. pneumoniae. The mutations that induce a high-level of macrolide resistance include an A to G transition at position 2063 and an A to C transversion at position 2064, whereas low-level resistance is induced by an A to G transition at position 2617. M. pneumoniae can be categorized into two genotypes (subtype 1 and subtype 2) on the basis of the DNA sequence of the P1 adhesion protein. 2 Previous studies have suggested that these two genotypes may co-circulate during an M. pneumoniae outbreak, 5 although it has been reported that the clinical severity of infection is not associated with the genotype. 6 We characterized macrolide resistance directly on M. pneumoniae-positive nasopharyngeal swabs (NPSs) taken from children hospitalized because of LRTIs during an outbreak of M. pneumoniae infections in Italy in 2010 by analysing the DNA sequence of domain V of 23S rRNA. The strains were subtyped by directly sequencing the MPN528a gene containing the single nucleotide polymorphism (SNP) used to discriminate between subtypes.
Patients and methods

Clinical samples
An outbreak of M. pneumoniae infections occurred in the late spring and summer of 2010 in Bari, a city in southern Italy with a population of 5 00000 people. The outbreak was identified as a result of the significant increase in the number of M. pneumoniae-positive NPSs; a 12% detection rate versus the average of 3% recorded during the same period in the previous 3 years. Of the 380 samples systematically collected from patients with LRTIs hospitalized at the Giovanni XXXIII regional paediatric referral hospital in Bari between April and September 2010, 46 samples from 41 children were positive for M. pneumoniae as shown by a commercial real-time PCR assay (LightMix w Kit Mycoplasma pneumoniae, Roche Diagnostics, Milan). Two other M. pneumoniae-positive NPS samples from patients 1011 and 1066 in Table 1 , collected outside the epidemic period, were also suitable for analysis. The clinical manifestations were pneumonia in 39 children (91%) and bronchitis in 4 (9%). In three patients (1421, 1488 and 1558 in Table 1 ), the symptoms persisted after 10 days of appropriate antibiotic treatment (clarithromycin 7.5 mg/kg/day in two intravenous doses or 15 mg/kg/day in two oral doses) and additional NPS samples were collected and analysed for M. pneumonia DNA. Twenty-two (51%) of the children were males and 21 (49%) were females, with a mean age of 7.39 years (range: 15 months-16 years).
Written informed consent was obtained from the parents of all the children included in the study, which was carried out in accordance with the principles of the Declaration of Helsinki and Italian and institutional standards.
Determination of macrolide resistance genotypes
A PCR assay followed by direct amplicon sequencing was developed to detect point mutations conferring resistance to macrolides in the M. pneumoniae 23S rRNA gene. Domain V of the 23S rRNA gene was amplified using previously described primers 7 and an aliquot of DNA extracted from NPSs and stored at 2808C. The primers used specifically amplify a 217 bp region of M. pneumoniae that includes positions 2063 and 2064.
The PCR was carried out in a volume of 50 mL containing 5 mL of total DNA, 1× High Fidelity PCR buffer, 2.0 mM MgSO 4 , 0.2 mM of each dNTP, 0.25 mM of each primer and 1 U of Platinum Taq DNA Polymerase (Invitrogen, Milan, Italy). The reaction mixture then underwent denaturation for 2 min at 948C and 35 PCR cycles, each consisting of 30 s at 948C, 30 s at 558C and 30 s at 688C, followed by a final extension step of 5 min at 688C. The amplified products were analysed by means of electrophoresis on a 2% agarose gel (Invitrogen, Milan, Italy) and visualization under ultraviolet light. The amplicons were purified using a QIAquick Purification Kit (Qiagen, Milan, Italy) and directly sequenced using amplification primers.
M. pneumoniae genotyping
Forty of 48 M. pneumoniae strains were typed by a sequence assay targeted on a subtype-specific nucleotide in the MPN528a gene at position 650584 of the M129 genome (an A in subtype 1 and a C in subtype 2 strains). The PCR was carried out using the primers MPN528a-F and MPN528a-R, which define an amplicon containing the SNP. 8 The remaining samples could not be sequenced because of the lack of DNA. The PCR and sequencing for M. pneumoniae genotyping were carried out as described above for the detection of macrolide resistance genotypes.
Statistical test
Fisher's exact test was used to compare proportions regarding the prevalence of macrolide resistance or susceptible genotypes of M. pneumoniae subtypes. A P value ,0.05 was considered statistically significant.
Results
Identification of macrolide resistance genotype by sequencing assay A macrolide resistance genotype was detected in 26% (11/43) of the children positive for M. pneumoniae. Seven strains showed the A2063G transition and the remaining four the A2064G transition ( Table 1 ). The A2063G mutation was detected in all three of the patients (1421, 1488 and 1558 in Table 1 ) who experienced persisting clinical symptoms after 10 days of clarithromycin therapy and had a suspected macrolide-resistant strain; the NPS samples collected upon admission of all three cases showed macrolide-susceptible strains.
Genotyping of M. pneumoniae strains
The two subtypes co-circulated; 33 of 40 strains (82.5%) were classified as subtype 1 and 7 (17.5%) as subtype 2.
Of the subtyped samples from nine patients whose strains showed finally resistance to macrolides, eight were subtype 1 and one was subtype 2. Of the samples from 31 patients showing a macrolide susceptible genotype, 25 were subtype 1 and 6 were subtype 2. There was no association between the macrolide-resistant isolates and M. pneumoniae subtype (P .0.05).
Discussion
LRTIs in the presence of M. pneumoniae infection are generally treated with macrolides because tetracyclines and fluoroquinolones are not recommended in children due to concerns about possible adverse effects. We here report for the first time the circulation of macrolide-resistant M. pneumoniae strains in Italy, with a high prevalence of macrolide resistance genotypes in clinical samples (26%) in comparison with those in other European countries. 9, 10 It is likely that this is due to the widespread empirical use of macrolides for LRTIs in Italy, especially in children.
The most interesting finding of this study is the acquisition of the A2063G mutation by three patients during the course of infection. Upon admission, their isolates showed a susceptible genotype, but they later showed macrolide resistance. It was not possible to determine precisely when the shift occurred, but our findings support the hypothesis that the emergence of resistance may have been related to drug administration, considering that all three patients received clarithromycin for at least 10 days. This once again underlines the importance of a rapid diagnostic assay to detect macrolide resistance, but also the need for repeat testing in patients whose symptoms persist Emergence of M. pneumoniae macrolide resistance in Italy Chironna et al.
despite antibiotic therapy. Furthermore, when managing serious confirmed M. pneumoniae infections and macrolide failure, consideration should be given to changing antibiotics in order to achieve a favourable clinical and microbiological response.
One limitation of this study is that we did not measure MICs, and no clinical isolates were obtained to validate the molecular assay results. However, it is widely acknowledged that the presence of A2063G and A2064G mutations is usually associated with erythromycin MICs of 64 mg/L or greater.
Although our findings indicated the co-circulation of subtype 1 and subtype 2, subtype 1 was detected in more than 82% of sequenced strains. One possible explanation is that the characterized strains of M. pneumoniae belong to an outbreak due to subtype 1. A high prevalence of M. pneumoniae subtype 1 (93%) was recently reported in clinical isolates from China, 4 but it was detected in only 52% of the patients affected during a community outbreak in Sweden. 6 Further studies are needed to clarify this issue and rectify the lack of information concerning subtype distribution in Italy. Phylogenetic analyses of a longer region of the P1 gene of M. pneumoniae may help to identify the relationships among M. pneumoniae strains. We found no association between M. pneumoniae subtypes and macrolide resistance or susceptibility.
In conclusion, we have documented the presence of macrolide-resistant M. pneumoniae strains in Italy for the first time. The prevalence of macrolide resistance genotypes in hospitalized children was higher (26%) than might be expected from other European studies, requiring further investigation. It would also be useful to investigate the resistance rates in adults. We do not believe that our data are sufficient to change the recommendations for empirical macrolide treatment of M. pneumoniae infections in children in Europe, but we do suggest careful consideration of the possibility of resistance in patients who do not show an appropriate clinical response to antibiotic therapy. This can be done more easily by means of rapid molecular assays. Finally, monitoring the macrolide resistance of M. pneumoniae has now become necessary in Italy and in the rest of Europe.
